Analyst Profile

Followed by 760 followers
.
Gena Wang

Gena Wang

Barclays
Wall Street Analyst
#499 out of 8,141 Wall Street Analysts
#973 out of 24,284 experts

Success Rate

48%
150 out of 315 transactions made a profit

Average Return

+13.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Gena Wang's trades since 2015 and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of 13.6% per rating.

Stock Rating Distribution

519Ratings
63.01% Buy
29.87% Hold
7.13% Sell
Distribution of Gena Wang's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Moderna
(MRNA)
Rating:Buy
Date:Aug 05, 2020 - Aug 05, 2021
Return:+449.10%
The most profitable rating made by Gena Wang

Gena Wang's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Tempest Therapeutics
Mar 17, 2015
Buy
Reiterated
$56.00
(3213.61% Upside)
2Ratings
0%
-69.80%
Pfizer
Jul 22, 2016
Buy
Assigned
1Ratings
0%
-5.30%
uniQure
Jul 22, 2016
Buy
Assigned
1Ratings
100%
+14.20%
Regeneron
Aug 17, 2016
Hold
Reiterated
1Ratings
0.00%
DRNA
Dicerna Pharma
Aug 17, 2016
Buy
Reiterated
1Ratings
0%
-14.60%
CASC
Cascadian Therapeutics
Nov 07, 2016
Buy
Reiterated
5Ratings
0%
-47.48%
~RXDX
Ignyta Inc
Nov 29, 2016
Buy
Reiterated
7Ratings
83%
+46.93%
Abeona Therapeutics
Jan 20, 2017
Buy
Initiated
1Ratings
100%
+192.00%
DMTX
Dimension Therapeutics Inc
Jan 31, 2017
Buy
Reiterated
10Ratings
33%
-38.92%
LOXO
Loxo Oncology
Feb 08, 2017
Buy
Initiated
1Ratings
100%
+119.50%
List of latest recommendations made by Gena Wang. Click to expand and see Gena Wang's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >